<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39359663</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1179-142X</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>International medical case reports journal</Title><ISOAbbreviation>Int Med Case Rep J</ISOAbbreviation></Journal><ArticleTitle>Normocomplementemic Urticarial Vasculitis Following Influenza Vaccination: A Case Report and Review of the Literature.</ArticleTitle><Pagination><StartPage>823</StartPage><EndPage>829</EndPage><MedlinePgn>823-829</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/IMCRJ.S483023</ELocationID><Abstract><AbstractText>Urticarial vasculitis is characterized by persistent urticarial lesions lasting over 24 h. Urticarial vasculitis is often triggered by medications, infections, and autoimmune disorders. However, vaccinations against viral and bacterial pathogens have recently been documented to induce urticarial vasculitis. We describe the case of a 67-year-old woman who was presented with an extensive erythematous and purpuric rash without systemic symptoms 3 days after an influenza vaccination. She was diagnosed with normocomplementemic urticarial vasculitis based on clinical findings, normal complement levels, and histopathological findings of leukocytoclastic vasculitis. After receiving oral histamines, she showed complete resolution 3 months after receiving the influenza vaccination. Although vaccination-associated vasculitis is common, urticarial vasculitis following vaccinations is rare. We reviewed 13 cases of urticarial vasculitis following a wide range of vaccines, including those against Bacillus Calmette-Guérin, serogroup B meningococcus, influenza, and coronavirus disease. We conducted a comprehensive review of various aspects, including age, sex, past medical history, type of vaccination, number of vaccinations, onset time, cutaneous symptoms, place of eruption, systemic symptoms, laboratory disorders, treatment period, and treatment of urticarial vasculitis. Two patients developed hypocomplementemic urticarial vasculitis after vaccination, and both experienced systemic symptoms such as arthralgia and fever. In this review, no significant differences were found in the data, which may be attributed to the small number of cases. The mechanisms underlying the induction of urticarial vasculitis by vaccines remain unknown; however, in addition to immune complex deposition and complement activation due to vaccine components, molecular mimicry may trigger urticarial vasculitis by producing vaccine-derived pathogenic antigen antibodies. This case study emphasizes the need for heightened awareness and further investigation of urticarial vasculitis as a rare adverse effect of vaccination.</AbstractText><CopyrightInformation>© 2024 Mima et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mima</LastName><ForeName>Yoshihito</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0009-0000-4832-1899</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, Tokyo Metropolitan Police Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, International University of Health and Welfare Hospital, Tochigi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohtsuka</LastName><ForeName>Tsutomu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Dermatology, International University of Health and Welfare Hospital, Tochigi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ebato</LastName><ForeName>Ippei</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Dermatology, International University of Health and Welfare Hospital, Tochigi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakata</LastName><ForeName>Yukihiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Dermatology, International University of Health and Welfare Hospital, Tochigi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakazato</LastName><ForeName>Yoshimasa</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Pathology, International University of Health and Welfare Hospital, Tochigi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norimatsu</LastName><ForeName>Yuta</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Dermatology, International University of Health and Welfare, Narita Hospital, Chiba, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Int Med Case Rep J</MedlineTA><NlmUniqueID>101566269</NlmUniqueID><ISSNLinking>1179-142X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">anticardiolipin antibody</Keyword><Keyword MajorTopicYN="N">molecular mimicry</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword><Keyword MajorTopicYN="N">vasculitis</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest related to this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>4</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39359663</ArticleId><ArticleId IdType="pmc">PMC11446193</ArticleId><ArticleId IdType="doi">10.2147/IMCRJ.S483023</ArticleId><ArticleId IdType="pii">483023</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kolkhir P, Grakhova M, Bonnekoh H, Krause K, Maurer M. Treatment of urticarial vasculitis: a systematic review. J Allergy Clin Immunol. 2019;143(2):458–466. doi:10.1016/j.jaci.2018.09.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2018.09.007</ArticleId><ArticleId IdType="pubmed">30268388</ArticleId></ArticleIdList></Reference><Reference><Citation>Misery L, Combemale P. BCG-vaccine-induced lupus vulgaris and urticarial vasculitis. Dermatology. 1993;186(4):274. doi:10.1159/000247372</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000247372</ArticleId><ArticleId IdType="pubmed">8513197</ArticleId></ArticleIdList></Reference><Reference><Citation>Velasco-Tamariz V, Prieto-Barrios M, Tous-Romero F, Palencia-Pérez SI, Postigo-Llorente C. Urticarial vasculitis after meningococcal serogroup B vaccine in a 6-year-old girl. Pediatr Dermatol. 2018;35(1):e64–e65. doi:10.1111/pde.13339</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pde.13339</ArticleId><ArticleId IdType="pubmed">29164681</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes R, Lacour JP, Baldin B, Reverte M, Ortonne JP, Passeron T. Urticarial vasculitis secondary to H1N1 vaccination. Acta Derm Venereol. 2010;90(6):651–652. doi:10.2340/00015555-0950</Citation><ArticleIdList><ArticleId IdType="doi">10.2340/00015555-0950</ArticleId><ArticleId IdType="pubmed">21057759</ArticleId></ArticleIdList></Reference><Reference><Citation>Ono H, Yamaguchi R, Shimizu A. Urticarial vasculitis after COVID-19 vaccination: a case report and literature review. Dermatol Ther. 2022;35(8):e15613. doi:10.1111/dth.15613</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dth.15613</ArticleId><ArticleId IdType="pmc">PMC9347495</ArticleId><ArticleId IdType="pubmed">35652448</ArticleId></ArticleIdList></Reference><Reference><Citation>Baraldi C, Boling LB, Patrizi A, et al. Unique cases of urticarial skin eruptions after COVID-19 vaccination. Am J Dermatopathol. 2022;44(3):198–200. doi:10.1097/DAD.0000000000002036</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/DAD.0000000000002036</ArticleId><ArticleId IdType="pubmed">34291744</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazzaro G, Maronese CA. Urticarial vasculitis following mRNA anti-COVID-19 vaccine. Dermatol Ther. 2022;35(3):e15282. doi:10.1111/dth.15282</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dth.15282</ArticleId><ArticleId IdType="pubmed">34931406</ArticleId></ArticleIdList></Reference><Reference><Citation>Dash S, Behera B, Sethy M, Mishra J, Garg S. COVID-19 vaccine-induced urticarial vasculitis. Dermatol Ther. 2021;34(5):e15093. doi:10.1111/dth.15093</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dth.15093</ArticleId><ArticleId IdType="pmc">PMC8420183</ArticleId><ArticleId IdType="pubmed">34369046</ArticleId></ArticleIdList></Reference><Reference><Citation>Daldoul M, Korbi M, Bellalah A, Ben Fadhel N, Belhadjali H, Zili J. Urticarial vasculitis triggered by SARS-CoV-2 vaccine (mRNA vaccine). J Eur Acad Dermatol Venereol. 2022;36(10):e743–e744. doi:10.1111/jdv.18253</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.18253</ArticleId><ArticleId IdType="pmc">PMC9348020</ArticleId><ArticleId IdType="pubmed">35604050</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson V, Seidenberg R, Caplan A, Brinster NK, Meehan SA, Kim RH. Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination. J Cutan Pathol. 2022;49(1):34–41. doi:10.1111/cup.14104</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cup.14104</ArticleId><ArticleId IdType="pmc">PMC8444807</ArticleId><ArticleId IdType="pubmed">34292611</ArticleId></ArticleIdList></Reference><Reference><Citation>Tihy M, Menzinger S, André R, Laffitte E, Toutous-Trellu L, Kaya G. Clinicopathological features of cutaneous reactions after mRNA-based COVID-19 vaccines. J Eur Acad Dermatol Venereol. 2021;35(12):2456–2461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8656287</ArticleId><ArticleId IdType="pubmed">34459036</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes GA, Desai M, Limone B, et al. A case series of cutaneous COVID-19 vaccine reactions at Loma Linda University Department of Dermatology. JAAD Case Rep. 2021;16:53–57. doi:10.1016/j.jdcr.2021.07.038</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdcr.2021.07.038</ArticleId><ArticleId IdType="pmc">PMC8372465</ArticleId><ArticleId IdType="pubmed">34423106</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwamura N, Eguchi K, Koga T, et al. Hypocomplementemic urticarial vasculitis case with hemophagocytic lymphohistiocytosis following SARS-CoV-2 mRNA vaccination. Immunol Med. 2023;46(2):97–107. doi:10.1080/25785826.2023.2193286</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/25785826.2023.2193286</ArticleId><ArticleId IdType="pubmed">36950829</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe T. Vasculitis following influenza vaccination: a review of the literature. Curr Rheumatol Rev. 2017;13(3):188–196. doi:10.2174/1573397113666170517155443</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1573397113666170517155443</ArticleId><ArticleId IdType="pubmed">28521688</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanker V, Mylavarapu M, Gupta P, Syed N, Shah M, Dondapati VVK. Post COVID-19 vaccination medium vessel vasculitis: a systematic review of case reports. Infection. 2024;52(4):1207–1213. doi:10.1007/s15010-024-02217-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-024-02217-w</ArticleId><ArticleId IdType="pubmed">38483787</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulva J, Simon R. Hypocomplementemic urticarial vasculitis (HUV) and hypocomplementemic urticarial vasculitis syndrome (HUVS); Background, pathogenesis, diagnosis, laboratory testing, management and treatment. J Autoimmun Res. 2017;4(3):1028.</Citation></Reference><Reference><Citation>Kulthanan K, Cheepsomsong M, Jiamton S. Urticarial vasculitis: etiologies and clinical course. Asian Pac J Allergy Immunol. 2009;27(2–3):95–102.</Citation><ArticleIdList><ArticleId IdType="pubmed">19839494</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Shamy A, Branch AD, Schiano TD, Gorevic PD. The complement system and C1q in chronic hepatitis C virus infection and mixed cryoglobulinemia. Front Immunol. 2018;9:1001. doi:10.3389/fimmu.2018.01001</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01001</ArticleId><ArticleId IdType="pmc">PMC5992393</ArticleId><ArticleId IdType="pubmed">29910796</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasiri S, Dadkhahfar S, Abasifar H, Mortazavi N, Gheisari M. Urticarial vasculitis in a COVID-19 recovered patient. Int J Dermatol. 2020;59(10):1285–1286. doi:10.1111/ijd.15112</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijd.15112</ArticleId><ArticleId IdType="pmc">PMC7436580</ArticleId><ArticleId IdType="pubmed">32880937</ArticleId></ArticleIdList></Reference><Reference><Citation>Greer JM, Longley S, Edwards NL, Elfenbein GJ, Panush RS. Vasculitis associated with malignancy. Experience with 13 patients and literature review. Medicine. 1988;67(4):220–230. doi:10.1097/00005792-198807000-00003</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005792-198807000-00003</ArticleId><ArticleId IdType="pubmed">3292873</ArticleId></ArticleIdList></Reference><Reference><Citation>Younis AA. Urticarial vasculitis as an initial manifestation of colonic carcinoma: a case report and review of the literature. Reumatismo. 2018;70(4):259–263. doi:10.4081/reumatismo.2018.1052</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/reumatismo.2018.1052</ArticleId><ArticleId IdType="pubmed">30570245</ArticleId></ArticleIdList></Reference><Reference><Citation>Maronese CA, Zelin E, Avallone G, et al. Cutaneous vasculitis and vasculopathy in the era of COVID-19 pandemic. Front Med Lausanne. 2022;9:996288. doi:10.3389/fmed.2022.996288</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.996288</ArticleId><ArticleId IdType="pmc">PMC9445267</ArticleId><ArticleId IdType="pubmed">36082274</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Kang J, Lee SG, Kim GT. COVID-19 vaccination-related small vessel vasculitis with multiorgan involvement. Z Rheumatol. 2022;81(6):509–512. doi:10.1007/s00393-022-01159-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00393-022-01159-8</ArticleId><ArticleId IdType="pmc">PMC9118190</ArticleId><ArticleId IdType="pubmed">35587834</ArticleId></ArticleIdList></Reference><Reference><Citation>Agmon-Levin N, Paz Z, Israeli E, Shoenfeld Y. Vaccines and autoimmunity. Nat Rev Rheumatol. 2009;5(11):648–652. doi:10.1038/nrrheum.2009.196</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2009.196</ArticleId><ArticleId IdType="pubmed">19865091</ArticleId></ArticleIdList></Reference><Reference><Citation>Segal Y, Shoenfeld Y. Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction. Cell Mol Immunol. 2018;15(6):586–594. doi:10.1038/cmi.2017.151</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cmi.2017.151</ArticleId><ArticleId IdType="pmc">PMC6078966</ArticleId><ArticleId IdType="pubmed">29503439</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>